Abbott Laboratories posts strong Q1 revenue and EPS growth
Updated
Updated · The Motley Fool · Apr 28
Abbott Laboratories posts strong Q1 revenue and EPS growth
10 articles · Updated · The Motley Fool · Apr 28
Abbott Laboratories reported nearly 8% year-over-year revenue growth and 6% EPS growth for Q1 2026, aided by its recent acquisition of Exact Sciences.
The company declared its 399th consecutive quarterly dividend and has increased payouts for 54 straight years, maintaining its Dividend Aristocrat status.
Abbott’s diversified portfolio, including cancer diagnostics and medical devices, supports resilience amid economic uncertainty and global trade disruptions, while its shares remain attractively valued below historical averages.
Can Abbott's $23B cancer bet outpace the threat GLP-1 drugs pose to its CGM business?
With new Medicare coverage, how fast will Abbott’s cancer screening sales actually grow?
How will massive Similac lawsuits affect Abbott's 54-year streak of dividend increases?
Why did Abbott's CEO buy $2 million in stock amid a 35% price crash?
What is Abbott’s total financial exposure from thousands of pending infant formula lawsuits?
How will US foreign aid cuts impact Abbott's sales of vital tests in developing nations?